Evidence map›Paper›PMID 37491566›Full record

ArticleAddiction (Abingdon, England)2023

Joint effects of substance use disorders and recent substance use on HIV viral non-suppression among people engaged in HIV care in an urban clinic, 2014-2019.

Catherine R Lesko, Oluwaseun O Falade-Nwulia, Jarratt D Pytell, Heidi E Hutton, Anthony T Fojo, Jeanne C Keruly, Richard D Moore, Geetanjali Chander

Open access · greenAbstract read
In one paragraph

Article in Addiction (Abingdon, England), 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
1.7field-weighted citation impact, top 16% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed, 9 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Observational
  5. Article
  6. Article
  7. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 3 institutions in 1 country.

Catherine R LeskoJohns Hopkins Bloomberg School of Public Health, Baltimore, Maryland, USA.ORCID 0000-0002-1717-2592
Oluwaseun O Falade-NwuliaJohns Hopkins School of Medicine, Baltimore, Maryland, USA.
Jarratt D PytellUniversity of Colorado Anschutz Medical Campus, Aurora, Colorado, USA.
Heidi E HuttonJohns Hopkins School of Medicine, Baltimore, Maryland, USA.
Anthony T FojoJohns Hopkins School of Medicine, Baltimore, Maryland, USA.
Jeanne C KerulyJohns Hopkins School of Medicine, Baltimore, Maryland, USA.
Richard D MooreJohns Hopkins School of Medicine, Baltimore, Maryland, USA.
Geetanjali ChanderUniversity of Washington School of Medicine, Seattle, Washington, USA.
Johns Hopkins University · USUniversity of Colorado Anschutz Medical Campus · USUniversity of Washington · US

Funding

Vaccine Response and Immunotherapeutics SWGP30AI094189 · NIAID · JOHNS HOPKINS UNIVERSITY · PI Richard E. Chaisson · 2012 to 2026
$67.0M
North American AIDS Cohorts on Collaboration and Design (NAACCORD)U01AI069918 · NIAID · JOHNS HOPKINS UNIVERSITY · PI Keri Nicole Althoff, RICHARD Douglas MOORE · 2006 to 2026
$65.2M
Johns Hopkins HIV Clinical CohortU01DA036935 · NIDA · JOHNS HOPKINS UNIVERSITY · PI MOORE, RICHARD DOUGLAS · 2014 to 2024
$14.9M
Alcohol Research Consortium in HIV: Relapse Prevention ArmP01AA029544 · NIAAA · JOHNS HOPKINS UNIVERSITY · PI HUTTON, HEIDI · 2021 to 2025
$7.1M
3/4 Alcohol Research Consortium in HIV - Epidemiological Research Arm (ARCH-ERA)U01AA020793 · NIAAA · UNIVERSITY OF WASHINGTON · PI CRANE, HEIDI M., LAU, BRYAN · 2011 to 2020
$5.8M
Ending the HIV Epidemic in Rural America (EHE-RA): Local Interventions, Co-Epidemics, and Social DeterminantsR01MD018539 · NIMHD · JOHNS HOPKINS UNIVERSITY · PI Anthony Todd Fojo · 2022 to 2026
$4.0M
1/4 Alcohol Research Consortium in HIV-Administrative Core (ARCH-AC)U24AA020801 · NIAAA · JOHNS HOPKINS UNIVERSITY · PI CHANDER, GEETANJALI, MCCAUL, MARY E · 2011 to 2021
$3.5M
Mentoring and Patient Oriented Research at the Nexus of Unhealthy Alcohol Use and HIVK24AA027483 · NIAAA · UNIVERSITY OF WASHINGTON · PI GEETANJALI CHANDER · 2019 to 2026
$1.3M
Optimizing outcomes at the intersection of HIV and mental health: Prediction, precision medicine, and population healthK08MH118094 · NIMH · JOHNS HOPKINS UNIVERSITY · PI FOJO, ANTHONY TODD · 2018 to 2022
$953k
The impact of social networks on hepatitis C transmission and care access in people who inject drugsK23DA041294 · NIDA · JOHNS HOPKINS UNIVERSITY · PI FALADE-NWULIA, OLUWASEUN · 2016 to 2020
$924k
Unhealthy alcohol use, other drug use, and mental health disorders: comorbidity burden in people with HIV, gaps in treatment, and impact on the HIV care continuumK01AA028193 · NIAAA · JOHNS HOPKINS UNIVERSITY · PI LESKO, CATHERINE · 2019 to 2023
$900k
NIAAA NIH HHS K01 AA028193NIAAA NIH HHS K24 AA027483NIAAA NIH HHS P01 AA029544NIAAA NIH HHS U01 AA020793NIAAA NIH HHS U24 AA020801NIAID NIH HHS P30 AI094189NIAID NIH HHS U01 AI069918NIDA NIH HHS K23 DA041294NIDA NIH HHS U01 DA036935NIMHD NIH HHS R01 MD018539NIMH NIH HHS K08 MH118094
6 · The paper itself

Abstract

aimsTo estimate the joint effects of substance use disorder (SUD) and recent substance use on human immunodeficiency virus (HIV) non-suppression.

designRetrospective clinical cohort study with repeated observations within individuals.

settingBaltimore, Maryland, United States.

participants1881 patients contributed 10 794 observations. MEASUREMENTS: The primary independent variable was the combination of history of SUD and recent substance use. History of SUD was defined as any prior International Classification of Diseases 9/10 code for cocaine or opioid disorder. Recent substance use was defined as the self-report of cocaine or non-prescribed opioid use on the National Institute of Drug Abuse-modified Alcohol, Smoking and Substance Involvement Screening Test or clinician-documented cocaine or opioid use abstracted from the medical record. The outcome was viral non-suppression, defined as HIV RNA >200 copies/mL on the first viral load measurement within 1 year subsequent to each observation of substance use. We adjusted for birth sex, Black race, age, HIV acquisition risk factors, years in care and CD4 cell count. In secondary analyses, we also adjusted for depressive, anxiety and panic symptoms, cannabis use and cannabis use disorder.

findingsOn their first observation, 31% of patients had a history of an SUD and 18% had recent substance use. Relative to no history of SUD and no recent substance use, the 1-year fully adjusted risk difference (RD) for viral non-suppression associated with cocaine and opioid use disorder and recent substance use was 7.7% (95% CI = 5.3%-10.0%), the RD was 5.5% (95% CI = 1.2%-9.7%) for history of cocaine use disorder without recent substance use, and the RD was 4.6% (95% CI = 2.7%-6.5%) for recent substance use without a SUD.

conclusionsSubstance use and substance use disorders appear to be highly prevalent among, and independently associated with, viral non-suppression among people with HIV.

Indexed as

CocaineHIV InfectionsOpioid-Related DisordersSubstance-Related DisordersAnalgesics, OpioidCohort StudiesHIVHumansRetrospective StudiesAnalgesics, OpioidCocainecocaine usehuman immunodeficiency virusmental healthopioid usesubstance use disorderviral suppression

Identifiers

PMID37491566
PMCPMC10592031
OpenAlexW4385264104

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.